Dose of Growth: Sanjivani Paranteral Converts 80,000 Warrants into Equity Shares

Sanjivani Paranteral Ltd, a pharmaceutical company involved in injectables and oral products, has approved conversion of 80,000 warrants into equity shares. The move is part of an ongoing capital restructuring exercise to enhance the equity base of the company and enable future growth.

Key highlights of the board ruling

- The conversion was also sanctioned via the preferential allotment route, according to SEBI's Issue of Capital and Disclosure Requirements Regulations
- Each warrant is entitled to get one equity share of ₹10 face value, at a premium of ₹20 per share
- The warrant holder who was not in the promoter group exercised the option by paying the remaining 75 percent of the issue price.

Shareholding and capital impact

1. Post-conversion, the company’s paid-up equity capital has increased to ₹20.98 crore, comprising 2,09,80,513 fully paid-up shares
2. The new shares will rank pari-passu with the existing equity shares and will be listed on BS
3. Promoter holding remains unchanged in this tranche, with public shareholding rising modestly
4. The balance of 47,68,667 warrants is subject to conversion within the 18-month exercise period

Why it matters

This conversion reflects investor optimism and provides Sanjivani Paranteral additional equity to support operations, R&D, and compliance with regulations. It is also a testament to the company's dedication to open capital structuring and long-term growth. 

Sources: BSE India, Business Standard, Moneycontrol, Screener.in